4FR Stock Overview
Operates as a clinical stage drug discovery and development company. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Faron Pharmaceuticals Oy Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£2.00 |
| 52 Week High | UK£3.80 |
| 52 Week Low | UK£1.04 |
| Beta | 0.31 |
| 1 Month Change | 13.90% |
| 3 Month Change | -21.72% |
| 1 Year Change | -44.98% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -43.18% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4FR | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 1.7% | -2.9% | -2.6% |
| 1Y | -45.0% | -14.7% | 6.9% |
Return vs Industry: 4FR underperformed the German Biotechs industry which returned -14.2% over the past year.
Return vs Market: 4FR underperformed the German Market which returned 7.1% over the past year.
Price Volatility
| 4FR volatility | |
|---|---|
| 4FR Average Weekly Movement | 9.5% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4FR's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 4FR's weekly volatility has decreased from 16% to 10% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 34 | Juho Jalkanen | www.faron.com |
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company’s lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the prevention from cytokine release syndrome (CRS), or ischemia and hyperinflammatory conditions; and Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. The company is also developing bexmarilimab, which is in phase 2 clinical trial for indications of solid tumors; and in phase 1 clinical trial for indications of acute myeloid leukemia and myelodysplastic syndromes.
Faron Pharmaceuticals Oy Fundamentals Summary
| 4FR fundamental statistics | |
|---|---|
| Market cap | €208.04m |
| Earnings (TTM) | -€31.61m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-6.6x
P/E RatioIs 4FR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4FR income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €31.61m |
| Earnings | -€31.61m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Feb 27, 2025
| Earnings per share (EPS) | -0.30 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 897.6% |
How did 4FR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 10:05 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Faron Pharmaceuticals Oy is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Patrick Trucchio | H.C. Wainwright & Co. |
| Marianne Palmu | Inderes Oy |
| Antti Siltanen | Inderes Oy |